Valérie Berlaimont (Valerie Berlaimont)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 7

Top Topics

Preterm Infants

Electronic Health Record

Top Venues

Human vaccines & immunotherapeutics

Expert review of vaccines

Sexually transmitted infections

This page only lists publications with an associated author ORCID identifier.

Publications

Marina George, Jaime Jesús Pérez-Martín, Mohammad AbdelGhany, Foteini Gkalapi, Nicolas Jamet, Richelle C Kosse, Yara Ruiz García, Elisa Turriani, Valérie Berlaimont
Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries. Human vaccines & immunotherapeutics (2023)
Pierre Bakhache, Vijay Yewale, Raunak Parikh, Gabriella Clancey, Gemma Spickernell, Valérie Berlaimont, Elisa Turriani
Diphtheria-tetanus-pertussis (DTP) vaccination: understanding the perspectives and expectations of parents and healthcare professionals in France and India. Human vaccines & immunotherapeutics (2021)
Santosh Soans, Attila Mihalyi, Valérie Berlaimont, Shafi Kolhapure, Resham Dash, Ashish Agrawal
Vaccination in preterm and low birth weight infants in India. Human vaccines & immunotherapeutics (2021)
Marco Costantini, Andrea Callegaro, Jiří Beran, Valérie Berlaimont, Ilaria Galgani
Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules. Human vaccines & immunotherapeutics 16 (9) (2020)
Marco Costantini, Andrea Callegaro, Jiří Beran, Valérie Berlaimont, Ilaria Galgani
Response letter: "Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules". Human vaccines & immunotherapeutics 16 (9) (2020)
Valérie Berlaimont, Sarah Welby
Response to 'Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017' by Checchi et al. Sexually transmitted infections 95 (7) (2019)
Martin Ryser, Valérie Berlaimont, Naveen Karkada, Attila Mihalyi, Rino Rappuoli, Robbert van der Most
Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types. Expert review of vaccines 18 (3) (2019)